Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting STING is a small interfering RNA designed to silence the expression of the Stimulator of Interferon Genes (STING) protein. STING is a central adapter protein in the cGAS-STING pathway, which detects cytosolic DNA (often resulting from DNA damage or viral infection) and triggers a proinflammatory response through the activation of TBK1, IRF3, and NF-κB. By degrading STING mRNA, this siRNA prevents the translation of the STING protein, thereby attenuating the production of inflammatory cytokines such as IL-6, MCP-1, and IFN-β. In preclinical research, particularly in models of atherosclerosis and DNA damage-induced inflammation, silencing STING has been shown to reduce vascular inflammation and plaque progression, suggesting its potential as a therapeutic target for chronic inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on siRNA targeting STING.